Galvanize Therapeutics is a technology company.
Galvanize Therapeutics has raised $200.0M across 2 funding rounds.
Galvanize Therapeutics has raised $200.0M in total across 2 funding rounds.
Galvanize Therapeutics has raised $200.0M in total across 2 funding rounds.
Galvanize Therapeutics's investors include Jonathan Waldstreicher, Seth L. Harrison, ATP (Apple Tree Partners), Norwest Venture Partners, Soffinova Partners.
Galvanize Therapeutics is a commercial-stage biomedical company developing pulsed electric field (PEF) technologies to treat diseases like solid tumors and chronic bronchitis by targeting pathologic cells non-thermally.[1][2][3] Its key products include the Aliya® PEF platform for oncology, aimed at ablating solid tumors and potentially stimulating immune responses, and RheOx® therapy for chronic bronchitis symptoms, addressing underserved patients beyond pharmaceutical options.[1][3][4] The company serves physicians, healthcare systems, and patients with these innovations, solving problems of limited efficacy in current treatments for metastatic cancers and debilitating lung conditions; it demonstrates strong growth momentum through a $100 million oversubscribed Series C in September 2025, FDA approvals for commercialization in the US, ongoing clinical trials, and board expansions.[1][3]
Galvanize Therapeutics emerged in late 2022 from a three-way merger of Apple Tree Partners (ATP) portfolio companies, each developing pulsed field ablation technologies for solid tumors, chronic bronchitis, and arrhythmias.[1][2] Incubated by ATP, a venture firm focused on biotech innovations, the company was formed in Redwood City, California, to consolidate and accelerate PEF platforms like Aliya and RheOx.[1][2][3] Early traction included first-in-human studies for RheOx showing safety and efficacy in chronic bronchitis, histopathologic validations, and pivotal clinical data presented in abstracts, setting the stage for US commercialization.[1][4]
Galvanize rides the wave of electroporation and PEF therapies in medtech, converging engineering, biology, and precision healthcare to challenge pharma-dominated treatments for oncology and chronic lung diseases.[2][3] Timing aligns with surging demand for non-invasive, immune-modulating alternatives amid rising cancer/metastatic cases and COPD burdens, bolstered by FDA nods and post-2025 funding for US expansion.[1][3] Market forces like underserved millions in solid tumors/chronic bronchitis favor its platform, influencing the ecosystem by pioneering PEF commercialization, fostering physician partnerships, and enabling data synergies with drugs.[2][3][4]
Galvanize is poised to scale US commercialization of Aliya and RheOx post-Series C, with funds fueling clinical expansion, platform innovation, and global ambitions beyond current US focus.[3] Trends like AI-driven trial design, immune-oncology synergies, and non-pharma chronic disease interventions will propel it, potentially evolving from PEF pioneer to global leader reshaping ablation standards.[1][3] As a 2022 merger success, its trajectory ties back to ATP's vision: delivering biologic-shifting medtech for patients long overlooked by pills alone.[1][2]
Galvanize Therapeutics has raised $200.0M across 2 funding rounds. Most recently, it raised $100.0M Series C in September 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2025 | $100.0M Series C | Jonathan Waldstreicher, Seth L. Harrison, ATP (Apple Tree Partners), Norwest Venture Partners, Soffinova Partners | |
| Sep 1, 2022 | $100.0M Series B | Jonathan Waldstreicher, Seth L. Harrison, ATP (Apple Tree Partners), Norwest Venture Partners, Soffinova Partners |